1. An optimized cyclophosphamide-treated mouse model of Mycobacterium abscessus pulmonary infection.
- Author
-
Sun Y, Zhang K, Delos Santos M, Pee CJE, Yang Y, Kang M, Shin SJ, Chan-Park MB, and Pethe K
- Subjects
- Animals, Mice, Imipenem pharmacology, Imipenem therapeutic use, Lung microbiology, Lung drug effects, Immunocompromised Host, Female, Cyclophosphamide pharmacology, Mycobacterium abscessus drug effects, Mycobacterium Infections, Nontuberculous drug therapy, Mycobacterium Infections, Nontuberculous microbiology, Disease Models, Animal, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Amikacin pharmacology, Amikacin therapeutic use
- Abstract
Mycobacterium abscessus pulmonary infections are increasingly problematic, especially for immunocompromised individuals and those with underlying lung conditions. Currently, there is no reliable standardized treatment, underscoring the need for improved preclinical drug testing. We present a simplified immunosuppressed mouse model using only four injections of cyclophosphamide, which allows for sustained M. abscessus lung burden for up to 16 days. This model proved effective for antibiotic efficacy evaluation, as demonstrated with imipenem or amikacin., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF